Adrian L Harris

Summary

Affiliation: Imperial Cancer Research Fund
Country: UK

Publications

  1. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
  2. ncbi Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor
    Rebecca J Appelhoff
    Henry Wellcome Bldg of Genomic Medicine, Roosevelt Drive, Headington, Oxford, UK
    J Biol Chem 279:38458-65. 2004
  3. doi Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues
    Juan Carlos Martinez
    CRUK Tumour Pathology Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
    Histopathology 54:598-606. 2009
  4. doi Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival
    Luke R G Pike
    Growth Factor Group, Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
    Biochem J 449:389-400. 2013
  5. doi Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 27:227-34. 2009
  6. ncbi Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas
    Gaynor J Bates
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK
    Breast Cancer Res Treat 111:453-9. 2008
  7. pmc Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer
    Ern Yu Tan
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Breast Cancer Res 9:R89. 2007
  8. ncbi Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 13:550-8. 2007
  9. ncbi Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer
    Daniele Generali
    Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Endocr Relat Cancer 13:921-30. 2006
  10. ncbi Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 67:11244-53. 2007

Collaborators

Detail Information

Publications127 found, 100 shown here

  1. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  2. ncbi Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor
    Rebecca J Appelhoff
    Henry Wellcome Bldg of Genomic Medicine, Roosevelt Drive, Headington, Oxford, UK
    J Biol Chem 279:38458-65. 2004
    ....
  3. doi Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues
    Juan Carlos Martinez
    CRUK Tumour Pathology Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
    Histopathology 54:598-606. 2009
    ..Our aim was to pursue this by raising a monoclonal antibody to the internal domain of DLL4 and assess its distribution in normal and malignant tissues in comparison with antibodies against the external domain of DLL4...
  4. doi Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival
    Luke R G Pike
    Growth Factor Group, Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
    Biochem J 449:389-400. 2013
    ..Collectively, the findings of the present study identify transcriptional up-regulation of ULK1 as a novel arm of the ISR, and suggest ULK1 as a potentially effective target for cancer therapy...
  5. doi Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 27:227-34. 2009
    ..We aimed to identify signaling pathways involved in the response and resistance to aromatase inhibitor therapy in patients with breast cancer...
  6. ncbi Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas
    Gaynor J Bates
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK
    Breast Cancer Res Treat 111:453-9. 2008
    ..FOXP1 is not estrogen regulated and silencing FOXP1 expression, using siRNA, did not affect ERalpha, ERbeta or progesterone receptor expression, suggesting ER and FOXP1 co-expression may reflect a common regulatory mechanism...
  7. pmc Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer
    Ern Yu Tan
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Breast Cancer Res 9:R89. 2007
    ..The present study investigates the role of FIH-1 in invasive breast carcinoma and its correlation with hypoxia...
  8. ncbi Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 13:550-8. 2007
    ..To examine the in vitro regulation of hepatocyte growth factor activator inhibitor type 2 (HAI-2) in breast cancer cells and the in vivo predictive role for the efficacy of chemoendocrine primary therapy in patients with breast cancer...
  9. ncbi Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer
    Daniele Generali
    Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Endocr Relat Cancer 13:921-30. 2006
    ..Studies investigating the effects of pH on tamoxifen uptake and the effects of therapy with CA inhibitors are planned...
  10. ncbi Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 67:11244-53. 2007
    ....
  11. ncbi Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells
    Laura S Harrington
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
    Microvasc Res 75:144-54. 2008
    ..The regulation of sVEGFR1 provides a novel mechanism for Dll4 signalling to regulate cells at distance, not just in adjacent cells...
  12. ncbi Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 14:2673-80. 2008
    ..However, the effects of endocrine therapy with aromatase inhibitors on in vivo expression of this signaling cascade, and its relation to tumor response and patient outcome, is unknown...
  13. ncbi BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer
    Ern Yu Tan
    Nuffield Department of Clinical Laboratory Sciences, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Clin Cancer Res 13:467-74. 2007
    ..Its perinecrotic localization within ductal carcinoma in situ (DCIS) suggests an involvement in neoplastic cellular adaptation to low oxygen tension. This study has investigated the role of BNIP3 in normal and neoplastic breast...
  14. ncbi Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Circ Res 95:162-9. 2004
    ..This represents a novel mechanism of action for hydralazine and presents HIF as a potential target for treatment of ischemic disease...
  15. doi The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth
    Jun Yang
    Growth Factor Group, Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, United Kingdom
    Cancer Res 70:6456-66. 2010
    ..Our findings provide a biological rationale to support the therapeutic targeting of histone demethylases in breast cancer patients...
  16. ncbi Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival
    Leticia Campo
    Nuffield Department Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
    J Pathol 205:585-91. 2005
    ..63) survival was observed in patients stratified by angiogenin expression. This study suggests that angiogenin may be important in breast cancer progression and that, through its relationship with ER, it may be a target for tamoxifen...
  17. doi An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3
    Anassuya Ramachandran
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Eur J Cancer 49:1741-51. 2013
    ..Thus, the knowledge based approach for deriving gene signatures can identify novel biologically relevant genes...
  18. pmc Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy
    Alan McIntyre
    Molecular Oncology Laboratories, Department of Medical Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    Clin Cancer Res 18:3100-11. 2012
    ..CAIX expression correlates with poor prognosis in most tumor types and with worse outcome in bevacizumab-treated patients with metastatic colorectal cancer, malignant astrocytoma, and recurrent malignant glioma...
  19. ncbi Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion
    Naomi Robertson
    Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 64:6160-5. 2004
    ..Thus, CAIX plays an important role in the growth and survival of tumor cells under normoxia and hypoxia, making it a potential target for cancer therapy, but is not involved in invasion...
  20. pmc Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
    Jonathan D Silk
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    J Clin Invest 114:1800-11. 2004
    ....
  21. ncbi Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia
    Alison H Banham
    Nuffield Department Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
    Prostate 67:1091-8. 2007
    ..This study investigated whether FOXP1 has a similar relationship to the androgen receptor (AR) in prostate cancer and how these factors relate to the presence of hypoxia...
  22. ncbi Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function
    Nilay S Patel
    Molecular Oncology Laboratories, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, London United Kingdom
    Cancer Res 65:8690-7. 2005
    ..We conclude that an optimal window of the DLL4 expression is essential for tumor angiogenesis and that selective modulation of the DLL4 expression within human tumors may represent a potential novel antiangiogenic therapy...
  23. doi The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib
    Manuela Milani
    Growth Factor Group, Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
    Cancer Res 69:4415-23. 2009
    ....
  24. doi Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths
    Pawel Swietach
    Department of Physiology, Anatomy, and Genetics, Burdon Sanderson Cardiac Science Centre, Oxford, UK
    J Biol Chem 283:20473-83. 2008
    ..We suggest that pH(i) coordination may favor survival and growth of a tumor. By disrupting spatial pH(i) control, inhibition of CA9 activity may offer a novel strategy for the clinical treatment of CA9-associated tumors...
  25. ncbi A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines
    Tsung Wen Chong
    Cancer Research United Kingdom, Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Cancer Res 62:6924-7. 2002
    ..DFE potentially could be useful in cancer therapy by inducing apoptosis via NIP3 in conjunction with other non-HIF-related growth inhibitory pathways and blocking endothelial proliferation despite the presence of VEGF...
  26. doi Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells
    Elena Favaro
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Cell Metab 16:751-64. 2012
    ..Thus, glycogen metabolism is a key pathway induced by hypoxia, necessary for optimal glucose utilization, which represents a targetable mechanism of metabolic adaptation...
  27. ncbi Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia
    Heidi M Sowter
    Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Cancer Res 63:6130-4. 2003
    ..Remarkably, among a panel of hypoxia-inducible genes, responses were critically dependent on Hif-1 alpha but not Hif-2 alpha in both endothelial and breast cancer cells but critically dependent on Hif-2 alpha in renal carcinoma cells...
  28. ncbi Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase
    Howard R Mellor
    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK
    Biochem Pharmacol 79:1562-72. 2010
    ..This study provides new insight into the post-translational functional control of these Bcl-2 family members...
  29. doi DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo
    Ji Liang Li
    Molecular Oncology Laboratories, Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 71:6073-83. 2011
    ....
  30. ncbi The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer
    Stuart C Winter
    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer 107:757-66. 2006
    ..Anemia may contribute to hypoxia by reducing oxygen delivery, but it is not known whether this influences HIF-alpha expression in tumors...
  31. pmc Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer
    Adrian M Jubb
    Nuffield Department of Clinical Laboratory Sciences, Weatherall Institute ofMolecular Medicine, University of Oxford, Oxford, UK
    Am J Pathol 176:2019-28. 2010
    ..002, respectively). In summary, Dll4 was expressed by endothelium associated with breast cancer cells. In these retrospective subset analyses, endothelial Dll4 expression was a statistically significant multivariate prognostic factor...
  32. doi New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes
    Helen Sheldon
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Blood 116:2385-94. 2010
    ..This reversal in phenotype appears to enhance vessel formation and is a new form of signaling for Notch ligands that expands their signaling potential beyond cell-cell contact...
  33. ncbi Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation
    Dylan T Jones
    Cancer Research UK Growth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK
    Clin Cancer Res 12:5384-94. 2006
    ..Therefore, Trx-1 and HIF-alpha are attractive molecular targets for novel cancer therapeutics...
  34. ncbi Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells
    Helen J Knowles
    Cancer Research United Kingdom Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS
    Cancer Res 63:1764-8. 2003
    ..These results indicate that both ascorbate and iron availability have major effects on HIF, and imply that the system is commonly regulated by limiting hydroxylase activity under normoxic tissue culture conditions...
  35. doi Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 15:1046-51. 2009
    ....
  36. doi Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms
    Sarah A Lowndes
    Cancer Research UK Department of Medical Oncology, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
    Microvasc Res 77:314-26. 2009
    ..RNA interference to AQP1 inhibited endothelial proliferation and migration, confirming the role of AQP1 in endothelial cell function. Therefore regulation of AQP1 may represent an important action of copper chelation therapy...
  37. ncbi Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
    Gaynor J Bates
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 24:5373-80. 2006
    ..To assess the clinical significance of tumor-infiltrating FOXP3-positive regulatory T cells (TR) in breast cancer patients with long-term follow-up...
  38. ncbi Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers
    Stuart C Winter
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital
    Cancer Res 67:3441-9. 2007
    ..The work highlights the validity and potential of using data from analysis of in vitro stress pathways for deriving a biological metagene/gene signature in vivo...
  39. ncbi Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer
    Nilay S Patel
    Growth Factor Group, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 12:4836-44. 2006
    ..To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis...
  40. doi Regulation of intracellular pH in cancer cell lines under normoxia and hypoxia
    Alzbeta Hulikova
    Department of Physiology, Anatomy, and Genetics, Oxford University, Oxford, UK
    J Cell Physiol 228:743-52. 2013
    ..In contrast, the more variable flux on NHE underlies cell-specific differences in their dynamic response to larger acid loads...
  41. doi Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma
    Adrian M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
    Histopathology 60:740-7. 2012
    ..The aims of this study were to characterize the expression of Dll4 and Jag1 in primary glioblastomas...
  42. ncbi Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer
    Daniele Generali
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 12:4562-8. 2006
    ....
  43. ncbi Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis
    Alexandra Giatromanolaki
    Department of Pathology, Democritus University of Thrace, Medical School, PO Box 12, Alexandroupolis 68100, Greece, and John Radcliffe Hospital, Oxford, UK
    Gynecol Oncol 103:912-8. 2006
    ..In this study, the expression of LDH-5 was assessed in the normal and malignant endometrium. Its role in prognosis and tumor angiogenesis and hypoxia was also examined...
  44. doi Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells
    Cassin Kimmel Williams
    Molecular Oncology Laboratories, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 68:1889-95. 2008
    ..Thus, Dll4 may contribute to vascular differentiation and inhibition of the angiogenic response by regulating multiple receptor pathways...
  45. ncbi Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara
    Caroline L Smith
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom
    J Immunol 175:8431-7. 2005
    ....
  46. doi Delta-like ligand 4-notch blockade and tumor radiation response
    Stanley K Liu
    DPhil, Molecular Oncology Unit, The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    J Natl Cancer Inst 103:1778-98. 2011
    ..Ionizing radiation can disrupt tumor vasculature, and Notch pathway inhibition can interfere with functional angiogenesis. We explored the potential cooperativity between Notch inhibition and ionizing radiation in delaying tumor growth...
  47. ncbi Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade
    Heidi Michelle Sowter
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    J Pathol 201:573-80. 2003
    ..BNip3 was present in tumour-associated macrophages and in apocrine metaplastic lesions. Expression of NIX did not correlate with any of the parameters investigated...
  48. doi hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer
    Harriet E Gee
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    Cancer 116:2148-58. 2010
    ..The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis...
  49. ncbi The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours
    Helen Turley
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    J Pathol 203:808-13. 2004
    ..Its interrelationship with other hypoxically regulated molecules, such as the hypoxia-inducible factors or carbonic anhydrase IX, and differentiation of tumours now requires further investigation...
  50. ncbi Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Cancer Res 66:2600-7. 2006
    ..These results indicate that physiologic changes in macrophage iron metabolism have an important effect on HIF hydroxylase pathways and suggest means by which the system could be manipulated for therapeutic benefit...
  51. ncbi microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer
    Francesca M Buffa
    Oncology Department, Weatherall Institute of Molecular Medicine, University of Oxford and Genomics Research, Wellcome Trust Centre for Human Genetics, Oxford, UK
    Cancer Res 71:5635-45. 2011
    ..Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets...
  52. ncbi Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence
    Caroline L Smith
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX3 9DS, UK
    Int J Cancer 113:259-66. 2005
    ....
  53. ncbi The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer
    Howard R Mellor
    Growth Factor Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK
    Cancer Metastasis Rev 26:553-66. 2007
    ..However, the mechanism through which BNIP3 induces autophagy and the cellular consequences of this are yet to be established...
  54. ncbi Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells
    Kurosh Ameri
    Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Blood 103:1876-82. 2004
    ..Thus, this study demonstrates a novel HIF-1alpha-independent anoxic mechanism that regulates ATF-4 induction at the protein stability level in tumor cells...
  55. ncbi Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding
    Dylan T Jones
    Cancer Research UK Growth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom
    Mol Cancer Ther 5:2193-202. 2006
    ..Our cell-based approach and deconvolution of the inhibitory effect of DJ12 has identified a novel compound that targets the hypoxia pathway by inhibiting Hif-alpha-inducible transcription...
  56. ncbi Angiogenesis in bladder cancer--prognostic marker and target for future therapy
    Edward H Streeter
    Imperial Cancer Research Fund Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Surg Oncol 11:85-100. 2002
    ..Evidence for its role in bladder carcinogenesis, its usefulness as a marker of patient prognosis, and potential anti-angiogenic therapies for future development are discussed in this chapter...
  57. doi Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles
    Shaveta Mehta
    University Department of Oncology, Molecular Oncology Laboratories, Medical Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    J Natl Cancer Inst Monogr 2011:71-4. 2011
    ..Our results illustrate how the combination of dynamic imaging data and gene expression profiles can guide the development of biomarkers for predicting response to antiangiogenic therapy...
  58. ncbi Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas
    Stephen B Fox
    Nuffield Department Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK
    Clin Cancer Res 10:3521-7. 2004
    ..The FOXP1 gene, which maps to 3p14, shows common loss of heterozygosity in breast tumors and is a candidate tumor suppressor gene. However, its role in breast cancer is unknown...
  59. doi The role of hypoxia regulated microRNAs in cancer
    Robert McCormick
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Curr Top Microbiol Immunol 345:47-70. 2010
    ..miR-210 expression correlates with poor survival in cancer patients, and shows promise for future use as a tumour marker or therapeutic agent. The role of miR-210 and other HRMs in cancer biology is the subject of this review...
  60. doi Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis
    Adrian M Jubb
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    J Cell Mol Med 14:18-29. 2010
    ..This review aims to discuss the clinical impact of translational work on hypoxia markers and to explore future directions for research in this area...
  61. ncbi The potential of new tumor endothelium-specific markers for the development of antivascular therapy
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
    Cancer Cell 11:478-81. 2007
    ....
  62. doi Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion
    Pawel Swietach
    Department of Physiology, Anatomy and Genetics, Parks Road, Oxford, UK
    BJU Int 101:22-4. 2008
  63. pmc Roles of tetrahydrobiopterin in promoting tumor angiogenesis
    Liye Chen
    Department of Clinical Pharmacology, University of Oxford, John Radcliffe Hospital, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Am J Pathol 177:2671-80. 2010
    ..Our findings suggest that BH4 synthesis may be a rational target for antiangiogenesis therapy for tumors...
  64. ncbi Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate
    Dylan T Jones
    Cancer Research UK Growth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Cancer Res 66:2749-56. 2006
    ..The use of anti-TfR mAbs and ascorbate in inhibiting both cell proliferation and HIF-1alpha and angiogenesis under normoxic conditions may be of therapeutic use...
  65. doi Targeting vascular endothelial growth factor in renal cell carcinoma
    Nilay S Patel
    Churchill Hospital, Oxford, UK
    Tumour Biol 30:292-9. 2009
    ....
  66. ncbi Hypoxia-inducible factors and hypoxic cell death in tumour physiology
    Andrea L Bacon
    Cancer Research UK, The Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Ann Med 36:530-9. 2004
    ..Understanding the mechanisms by which HIF-1 induces cell death and the manner in which the tumour cell can overcome such signals, is critical for our understanding of cancer progression and the development of effective therapeutics...
  67. ncbi Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Biochem Pharmacol 71:646-56. 2006
    ..This suggests a novel mechanism(s) mediating the clinical effects of pharmacological doses of niacin...
  68. ncbi Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target
    Christian Potter
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital Oxford, UK
    Cell Cycle 3:164-7. 2004
    ..As it is commonly expressed in tumours with the worst prognosis it is a potential target for therapy...
  69. ncbi The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway
    Russell D Leek
    Growth Factor Group, Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Res 65:4147-52. 2005
    ..These results indicate that the enhancing effect of HIF-1 in three-dimensional tumor growth is a balance of both reduced proliferation and enhanced survival, the latter being proportionally greater...
  70. pmc MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU
    Elena Favaro
    Genomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    PLoS ONE 5:e10345. 2010
    ..Hypoxia in cancers results in the upregulation of hypoxia inducible factor 1 (HIF-1) and a microRNA, hsa-miR-210 (miR-210) which is associated with a poor prognosis...
  71. ncbi Macrophage infiltration and angiogenesis in human malignancy
    Helen Knowles
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, Oxford OX3 9DU, UK
    Novartis Found Symp 256:189-200; discussion 200-4, 259-69. 2004
    ....
  72. ncbi Histological quantitation of tumour angiogenesis
    Stephen B Fox
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    APMIS 112:413-30. 2004
    ..Gene arrays may be able to provide an angiogenesis profile. Continued study into the processes involved in generating a tumour blood supply is likely to identify new markers that may be more accurate measures...
  73. ncbi c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism
    Ulrike E Knies-Bamforth
    Molecular Oncology Laboratory, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 64:6563-70. 2004
    ..Blocking VEGF signaling in vivo significantly reduced dermal angiogenesis, demonstrating the importance of VEGF as a mediating factor for the c-Myc-induced angiogenic phenotype...
  74. ncbi Role of hypoxia-inducible factor-1alpha as a cancer therapy target
    Shalini Patiar
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Endocr Relat Cancer 13:S61-75. 2006
    ..Several novel small molecule inhibitors of HIF-1 have been identified and are moving towards clinical trials, but none of these are specific for HIF-1. Further work is ongoing to identify more selective HIF-1 inhibitors...
  75. ncbi Notch signaling from tumor cells: a new mechanism of angiogenesis
    Ji Liang Li
    Cancer Research UK Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Cancer Cell 8:1-3. 2005
    ..Selective interruption of Notch signaling within tumors may provide an antiangiogenic strategy...
  76. ncbi Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
    Ji Liang Li
    Cancer Research UK Molecular Oncology Department, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
    Front Biosci (Landmark Ed) 14:3094-110. 2009
    ..Thus, targeting the DLL4/Notch pathway, though still at an early stage, may lead to exciting new therapies for clinical application...
  77. ncbi Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion
    Adam Jones
    Imperial Cancer Research Fund, University of Oxford Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom
    J Urol 167:1482-6. 2002
    ..We report that it is not merely an incidental finding. Thymidine phosphorylase has a functional role in bladder cancer invasion...
  78. ncbi Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
    Richard C A Sainson
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Trends Mol Med 13:389-95. 2007
    ..Altogether, these molecules constitute a new category of pro-angiogenic yet anticancer agents and offer an exciting alternative to previously described vascular targeting molecules...
  79. ncbi NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells
    Ian F Hermans
    Tumor Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:5140-7. 2003
    ..Thus, iNKT cells exert a significant influence on the efficacy of immune responses to soluble Ag by modulating DC function...
  80. ncbi Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials
    Wen Shi
    Molecular Oncology Laboratories, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, UK
    J Mammary Gland Biol Neoplasia 11:41-52. 2006
    ..A variety of strategies for blocking Notch signaling, in particular gamma-secretase inhibition, are discussed as potential therapies for breast cancer and tumor angiogenesis...
  81. ncbi The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis
    Emma Hormbrey
    Weatherall Institute of Molecular Medicine, Oxford OX3 9DU, UK
    Clin Cancer Res 9:4332-9. 2003
    ..This study describes the profile of VEGF production in human surgical wounds in both breast cancer patients and reduction mammoplasty controls, and assesses the changes in systemic VEGF levels and platelet profiles perioperatively...
  82. ncbi Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation
    Kevin J Turner
    Imperial Cancer Research Fund Molecular Oncology Laboratory and Angiogenesis Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Cancer Res 62:2957-61. 2002
    ..These results suggest that activation of the HIF pathway is functionally important in CC-RCC development and might provide a new therapeutic target...
  83. ncbi Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases
    Jun Yang
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Ann N Y Acad Sci 1177:185-97. 2009
    ..This provides a new mechanism for regulation of the response to hypoxia...
  84. doi Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies
    Richard C A Sainson
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK
    Angiogenesis 11:41-51. 2008
    ....
  85. ncbi Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer
    Cory S M Williams
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    J Pathol 200:195-206. 2003
    ....
  86. ncbi Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data
    Marialena Trivella
    Cancer Research UK NHS Centre for Statistics in Medicine, Oxford, UK
    Lancet Oncol 8:488-99. 2007
    ..We aimed to collect individual patient data to assess microvessel-density counts (ie, a measure of angiogenesis) as a prognostic factor in non-small-cell lung carcinoma...
  87. ncbi Hypoxia-regulated differentiation: let's step it up a Notch
    Richard C A Sainson
    Cancer Research UK, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Trends Mol Med 12:141-3. 2006
    ..The identification of this crosstalk between pathways that are often deregulated in cancer is groundbreaking and opens up new areas for cancer research...
  88. ncbi Inclusion of vasculature-related variables in the Dukes staging system of colon cancer
    Michael I Koukourakis
    Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece, and Department of Pathology, John Radcliffe Hospital, UK
    Clin Cancer Res 11:8653-60. 2005
    ..Improvement of the Dukes stage predictive accuracy is necessary to better assign patients for adjuvant therapies, especially nowadays when antiangiogenic agents are being incorporated in the clinical practice...
  89. ncbi Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2
    Veronica A Carroll
    Molecular Oncology Laboratory, Cancer Research UK, The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Arterioscler Thromb Vasc Biol 25:736-41. 2005
    ..Some kringle domains of hemostatic proteins are antiangiogenic and promote apoptosis. The objective of this study was to investigate whether K2P is an angiogenesis inhibitor because of the presence of kringle 2...
  90. ncbi The unfolded protein response and integrated stress response to anoxia
    Tomasz Rzymski
    Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Clin Cancer Res 13:2537-40. 2007
    ..Therefore, targeting additional components of anoxic pathways, besides the hypoxia-inducible response, may be effective for future anticancer therapies...
  91. ncbi Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas
    Efthimios Sivridis
    Department of Pathology, Democritus University of Thrace, Alexandroupolis 68100, Greece
    J Pathol 196:416-22. 2002
    ..TP is not an effective contributor to the angiogenic process, but is associated with aggressive histological features. The two factors, when co-expressed, play a co-operative role in the induction of angiogenesis...
  92. ncbi Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia
    Margaret J Currie
    Pathology Department, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    J Pathol 198:502-10. 2002
    ..These data suggest that it is endothelial induction of Ang-2 in tumours that regulates vessel stability and supports targeting Tie2 as an effective novel anti-angiogenic therapy in clear cell RCCs...
  93. ncbi DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer
    Alexandra Giatromanolaki
    Departments of Pathology and Radiotherapy Oncology, Democritus University of Thrace, Alexandroupolis 68100, Greece
    J Pathol 200:222-8. 2003
    ..It is suggested that loss of DEC1 expression is an early event in the development of lung cancer, while DEC1 gene expression occurs in a subset of tumours and parallels the overexpression of other hypoxia-regulated proteins...
  94. ncbi Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway
    John R Griffiths
    CRC Biomedical Magnetic Resonance Research Group, Department of Biochemistry and Immunology, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Cancer Res 62:688-95. 2002
    ..They suggest potential biochemical targets that may be modified by therapy blocking HIF-1 function...
  95. ncbi A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis
    Kaye J Williams
    School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, M13 9PL, UK
    Oncogene 21:282-90. 2002
    ..Compromised glucose uptake and metabolic adaptation to the tumour micro-environment may form the basis of the reduced tumorigenicity associated with these cells...
  96. pmc Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis
    Alexandra Giatromanolaki
    Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece
    Arthritis Res Ther 5:R193-201. 2003
    ..The activation of the HIF-alpha pathway occurs in both RA and OA, although for unrelated reasons...
  97. ncbi Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes
    Peter Birner
    Institute of Clinical Pathology, University of Vienna, Austria
    Brain Pathol 13:133-43. 2003
    ..Our findings denote for the first time distinct angiogenic subtypes of human glioblastoma which may prove relevant for anti-angiogenic therapy approaches...
  98. ncbi GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding
    Rachel E Airley
    School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, United Kingdom
    Int J Cancer 104:85-91. 2003
    ..009). Thus, our study has shown that HIF-1 regulated genes have potential for future use as predictors of the malignant changes mediated by hypoxia, and warrant further investigation as indicators of response to cancer therapy...
  99. ncbi Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer
    Nigel J P Beasley
    Oxford Centre for Head and Neck Oncology, Radcliffe Infirmary, Oxford OX2 6HE, United Kingdom
    Cancer Res 62:1315-20. 2002
    ..017), but no obvious correlation with intratumoral lymphatics. Our results provide new evidence that proliferating lymphatics can occur in human cancers and may in some cases contribute to lymph node metastasis...
  100. ncbi The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography
    David R Collingridge
    Cancer Research UK Positron Emission Tomography Oncology Group, Department of Cancer Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London W12 0NN
    Cancer Res 62:5912-9. 2002
    ..These studies support further development of [(124)I]-SHPP-VG76e as a radiotracer for measuring tumor levels of VEGF in humans...
  101. ncbi Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma
    Efthimios Sivridis
    Department of Pathology, Democritus University of Thrace, Alexandroupolis, Greece
    Cancer 95:1055-63. 2002
    ....